Phase 2 N=71 A Study of TAK-861 in Participants With Narcolepsy Type 2
Narcolepsy Type 2
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — 2.14; 1.90; 4.54 minutes — p==0.989
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=112 A Study of TAK-861 in Participants With Narcolepsy Type 1
Narcolepsy Type 1
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — -1.16; 12.49; 23.50; 25.42 minutes — p==0.001
Phase 3 N=231 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
Narcolepsy
Primary: Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — -2.72; 0.58; -0.53; 2.68 Minutes — p=<0.001
N/A N=210 A Study to Collect Information of People With Narcolepsy in Spain
Narcolepsy
Primary: Percentage of Participants Categorized Based on Treatment by Narcolepsy Type Since Diagnosis up to Study Visit — 5.10; 7.55; 94.90; 92.45 percentage of participants…
Phase 1 N=58 Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy
Healthy Participants and Patients With Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 1; 1; 1 Participants
Phase 2 N=44 Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
Idiopathic Hypersomnia · Narcolepsy Without Cataplexy
Primary: Change in Epworth Sleepiness Scale (ESS) Score — 5.0; 4.4 score on a scale
Phase 1 N=57 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy
Healthy Participants · Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 0; 2; 4 Participants
N/A N=60 Awareness and Self-Compassion Enhancing Narcolepsy Treatment
Narcolepsy · Narcolepsy Without Cataplexy · Narcolepsy With Cataplexy
Primary: Number of Participants Who Attended ≥ 80% of Sessions — 15; 13; 15 Participants
Phase 3 N=247 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
Excessive Daytime Sleepiness · Narcolepsy · Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Primary: Number of Responders to the Patient Global Impression of Change (PGI-C) Ratings — 241 Participants
Phase 2 N=48 Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
Narcolepsy
Primary: Epworth Sleepiness Scale (ESS) — 14.68; 15.34; 15.34 score on a scale
Phase 3 N=236 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
Narcolepsy
Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 2.12; 4.74; 9.77; 12.27 minutes
Phase 3 N=196 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
Narcolepsy
Primary: Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks — 2.6; 1.3; -1.9; 1.9 Minutes — p=0.0024
Phase 3 N=28 Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
Nocturia · Daytime Sleepiness
Primary: Change From Baseline in Epworth Sleepiness Scale [ESS] — 9.03; 9.73 units on a scale
Phase 2 N=93 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
Narcolepsy
Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last…
Phase 2 N=24 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
Narcolepsy · Excessive Sleepiness
Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 20.46; 19.08 centimeter (cm) — p=0.0022
Phase 2 N=190 A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
Narcolepsy
Primary: Epworth Sleepiness Scale — -5.1; -5.6; -3.3 score on a scale — p=0.024
Phase 2 N=137 Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients
Primary Insomnia
Primary: Latency to Persistent Sleep — -22.7; -39.1; -37.5 minutes
Phase 3 N=328 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
Narcolepsy · Sleep Apnea, Obstructive · Sleep Apnea Syndromes
Primary: Safety and Tolerability as Measured by Number of Participants With Adverse Events — 323 Participants
Phase 2 N=95 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Excessive Daytime Sleepiness · Narcolepsy
Primary: Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase — 6.30; 5.81; 1.29; 1.10 minutes — p=0.418
Phase 3 N=201 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Narcolepsy With Cataplexy
Primary: Change in Weekly Number of Cataplexy Attacks — 0.00; 2.35 attacks
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Myotonic Dystrophy, Type 1 (DM1) · Myotonic Dystrophy
Primary: Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo — 0; 0; 1; 1…
Phase 3 N=110 Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Narcolepsy With Cataplexy · Narcolepsy Without Cataplexy
Primary: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. — -6.29; -2.60 score on a scale
Phase 2 N=33 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
Narcolepsy
Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With…
Phase 2 N=135 Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
Sleep Deprivation
Primary: Maintenance of Wakefulness Test (MWT) — 23.3; 27.9; 29.3; 27.6 Minutes — p=<0.0001
Phase 2 N=10 Flumazenil for the Treatment of Primary Hypersomnia
Hypersomnia · Primary Hypersomnia · Idiopathic Hypersomnia
Primary: Change in Psychomotor Vigilance Task (PVT) Median Reaction Time — -9.86; -4.46 msec — p=0.77
Phase 3 N=212 Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
Excessive Daytime Sleepiness · Cataplexy · Narcolepsy
Primary: Maintenance of Wakefulness Test (MWT) — 10.8; 4.7 minutes — p=<0.001
N/A N=21 Modafinil, Sleep, and Cognition in Cocaine Dependence
Cocaine Dependence · Substance-induced Sleep Disorder · Substance-induced Cognitive Disorder
Primary: Total Sleep Time (Minutes) — 364; 379 Minutes
Phase 3 N=427 Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder
Excessive Sleepiness
Primary: Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2 — 7.7; 11.7; 4.8 Minutes — p=<0.0001
Phase 3 N=59 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
Narcolepsy
Primary: Adverse Experiences — 54 participants
Phase 1 N=28 A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
Idiopathic Hypersomnia
Primary: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) — 14.8; 40.0 percentage of participants